RESMED INC reported revenue of $1.46B for the period ended 2026-06-30, +8.6% year on year. Net income was $0.38B, a 26.2% net margin on a 58.8% gross margin. Free cash flow for the period was $1.65B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | $1.46B | +8.6% |
| Gross profit | $0.86B | — |
| Operating income | $0.45B | — |
| Net income | $0.38B | +1.0% |
| Gross margin | 58.8% | Net margin 26.2% |
| Revenue Q/Q | +2.3% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | $0.60B | 41.2% |
| R&D | $0.11B | 7.2% |
| SG&A | $0.29B | 19.9% |
| Tax & other | $0.07B | 4.5% |
| Item | Amount |
|---|---|
| Total assets | $8.97B |
| Total liabilities | $2.38B |
| Shareholders' equity | $6.59B |
| Equity / assets | 73.4% |
| Operating cash flow | $1.81B |
| Capital expenditure | $0.16B |
| Free cash flow | $1.65B |
| Cash conversion (OCF / net income) | 119% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
RVTY ・ HOOD ・ ROK ・ ROL ・ ROP ・ ROST ・ RCL ・ SPGI ・ CRM ・ SNDK ・ SBAC ・ SLB
Source: SEC EDGAR · This page shows public filing data only, not investment advice. · Browse all companies